The presence of a large geriatric and target patient population and the improving healthcare infrastructure in several APAC countries are expected to offer growth opportunities in the market during the forecast period. 

The market for osteoarthritis therapeutics is anticipated to be marginally affected due to the outbreak of COVID-19. Among drug types, the use of corticosteroids has reduced. Although there is no evidence to suggest that corticosteroid injections lead to a substantial increase in the risk of infection, there is a possible reduction in the immune response for up to a few weeks following the procedure. 

It should also be noted that the WHO, in one of its guidelines for the management of severe acute respiratory infection in patients with coronavirus, suggested avoiding systemic corticosteroids.  

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209565994 

Topical, oral, and parenteral pain medications are widely used to manage pain associated with osteoarthritis. Although alternatives such as orthopedic braces are used as part of a noninvasive approach for pain management, the adoption of pain medications for the condition is high owing to the ease of administration and the affordability of pain medications. 

The adoption of pain medications for the management of pain associated with osteoarthritis is expected to remain high over the coming decade, which is anticipated to propel the growth of the market during the study period. 

Remarkable advances have been made in diagnosing, treating, and monitoring disease activity in patients with osteoarthritis, including the conceptualization of personalized OA medications. Essential features of biomarkers that will have clinical relevance for a personalized approach to therapy for RA include the ease of measurement, acceptable levels of sensitivity and specificity, and test methods that are accessible and interpretable by clinicians. 

Based on anatomy, the market is segmented into knee, hip, hand, and small-joint osteoarthritis therapeutics. Knee osteoarthritis therapeutics is the largest and the fastest-growing segment in this market. This can primarily be attributed to the high incidence of knee osteoarthritis.